SCHEMBL3979999

SCHEMBL3979999

Cc1ccc(C)c(-n2nc(-c3ccc(F)cc3)cc2Nc2ncccc2C(N)=O)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.47
MAPT P10636 5/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
NPC1 O15118 4/20 0.47
AHR P35869 1/20 0.47
LMNA P02545 2/20 0.44
ALDH1A1 P00352 2/20 0.42
HPGD P15428 1/20 0.42
MAP4K2 Q12851 5/20 0.42
MTOR P42345 1/20 0.42
HTT P42858 1/20 0.41
SYK P43405 3/20 0.40
CDC7 O00311 1/20 0.40
PLK4 O00444 1/20 0.40
DYRK3 O43781 1/20 0.40
ROCK2 O75116 1/20 0.40
PRKD3 O94806 1/20 0.40
MAP4K4 O95819 1/20 0.40
CDK1 P06493 1/20 0.40
CSF1R P07333 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3974452 0.94 LMNA (0.48) RAB9AMAPTSMN1; SMN2NPC1AHR
SCHEMBL3861464 0.92 DHODH (0.48) RAB9AMAPTNPC1LMNAALDH1A1
SCHEMBL4248560 0.91 MAP4K2 (0.47) RAB9AMAPTSMN1; SMN2NPC1AHR
SCHEMBL3975028 0.86 SMN1; SMN2 (0.38) RAB9AMAPTSMN1; SMN2NPC1LMNA
SCHEMBL3977218 0.86 DHODH (0.50) RAB9AMAPTNPC1LMNAHTT
SCHEMBL3859778 0.84 LMNA (0.50) RAB9AMAPTNPC1LMNAALDH1A1
SCHEMBL3973559 0.83 MAP4K2 (0.50) RAB9AMAPTSMN1; SMN2NPC1AHR
SCHEMBL3974247 0.83 RAB9A (0.52) RAB9AMAPTSMN1; SMN2NPC1AHR
SCHEMBL3974462 0.82 DHODH (0.48) RAB9AMAPTNPC1LMNANTRK1
SCHEMBL3973042 0.82 DHODH (0.51) RAB9AMAPTNPC1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES BAYER PHARMACEUTICALS CORPORATION (US) 2009-08-20 US disclosed
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES BAYER PHARMACEUTICALS CORPORATION (US) 2009-08-20 US disclosed
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES BAYER PHARMACEUTICALS CORPORATION (US) 2009-08-20 US disclosed
US-7517878-B2 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARAMCEUTICALS CORPORATION (US) 2009-04-14 US disclosed
US-7517878-B2 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARAMCEUTICALS CORPORATION (US) 2009-04-14 US disclosed
US-7517878-B2 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARAMCEUTICALS CORPORATION (US) 2009-04-14 US disclosed
US-20050192294-A1 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARMACEUTICALS CORPORATION (US) 2005-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050192294-A1 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes GPR119, GOT2, IAPP RAB9A 2873/4885MAPT 3713/4885SMN1; SMN2 4413/4885
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES GPR119, GOT2, IAPP RAB9A 2873/4885MAPT 3713/4885SMN1; SMN2 4413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.